SanBio Company Limited (OTCMKTS:SNBIF – Get Free Report) shares fell 74.6% during trading on Wednesday. The stock traded as low as C$5.51 and last traded at C$5.85. 18,762 shares traded hands during mid-day trading, an increase of 2,756% from the average daily volume of 657 shares. The stock had previously closed at C$23.00.
SanBio Price Performance
The business has a 50-day moving average of C$9.94 and a 200 day moving average of C$10.05.
SanBio Company Profile
SanBio Co, Ltd. is a Japan-based biotechnology company focused on developing regenerative cell therapies for disorders of the central nervous system. The company’s research is aimed at repairing or restoring neurological function in patients with conditions that have limited treatment options, including chronic traumatic brain injury and stroke.
SanBio’s lead investigational product, SB623, is a cell-based therapy derived from allogeneic bone marrow mesenchymal stem cells. In Japan, the product received conditional and time-limited approval under the name AKUUGO Injection for the treatment of chronic motor dysfunction caused by traumatic brain injury.
Further Reading
- Five stocks we like better than SanBio
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for SanBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SanBio and related companies with MarketBeat.com's FREE daily email newsletter.
